Literature DB >> 7546905

Frequency of provirus-bearing CD4+ cells in HIV type 1 infection correlates with extent of in vitro apoptosis of CD8+ but not of CD4+ cells.

M Carbonari1, M Cibati, A M Pesce, D Sbarigia, P Grossi, G D'Offizi, G Luzi, M Fiorilli.   

Abstract

Lymphocytes from HIV-1-infected subjects undergo massive apoptosis when cultured in vitro, and this phenomenon might reflect pathogenetic mechanisms leading to immune dysfunction in vivo. However, (1) lymphocyte death is not restricted to CD4+ cells but seems to involve predominantly CD8+ cells, and (2) the same phenomenon occurs in other viral infections. Furthermore, it is not known whether a relationship exists between the HIV-1 burden and this type of cell death. In this work we sought to determine whether the HIV-1 provirus load correlates with the propensity to apoptosis of CD4+ and CD8+ cells. We studied 10 HIV-1-infected patients with CD4+ cell counts above 500/mm3 and free of concomitant infections. We correlated the frequency of HIV-1-infected CD4+ cells with the extent of culture-induced apoptosis as well as with the phenotype of the apoptotic lymphocytes. We found that the magnitude of apoptosis correlated with the frequency of HIV-1-infected CD4+ cells (p = 0.0007), and that increasing viral load and apoptosis were associated with a shift to the selective death of CD8+ cells. Our data support the view that, in addition to CD4+ cell killing, another immunopathogenic effect of HIV might be that of priming CD8+ cells to apoptosis. In vivo, this could eventually lead to the exhaustion of the cytotoxic T cell compartment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7546905     DOI: 10.1089/aid.1995.11.789

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  9 in total

Review 1.  Immune dysregulation and CD4+ T cell loss in HIV-1 infection.

Authors:  L Meyaard; F Miedema
Journal:  Springer Semin Immunopathol       Date:  1997

2.  Recombinant human IL-16 inhibits HIV-1 replication and protects against activation-induced cell death (AICD).

Authors:  T Idziorek; J Khalife; O Billaut-Mulot; E Hermann; M Aumercier; Y Mouton; A Capron; G M Bahr
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

3.  Loss of CD4+ T cells in human immunodeficiency virus type 1-infected chimpanzees is associated with increased lymphocyte apoptosis.

Authors:  I C Davis; M Girard; P N Fultz
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 4.  T helper cell activation and human retroviral pathogenesis.

Authors:  K F Copeland; J L Heeney
Journal:  Microbiol Rev       Date:  1996-12

5.  Distinct mechanisms of CD4+ and CD8+ T-cell activation and bystander apoptosis induced by human immunodeficiency virus type 1 virions.

Authors:  Geoffrey H Holm; Dana Gabuzda
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Dendritic cells infected with vpr-positive human immunodeficiency virus type 1 induce CD8+ T-cell apoptosis via upregulation of tumor necrosis factor alpha.

Authors:  Biswanath Majumder; Narasimhan J Venkatachari; Elizabeth A Schafer; Michelle L Janket; Velpandi Ayyavoo
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

7.  Apoptosis of bystander T cells induced by human immunodeficiency virus type 1 with increased envelope/receptor affinity and coreceptor binding site exposure.

Authors:  Geoffrey H Holm; Chengsheng Zhang; Paul R Gorry; Keith Peden; Dominique Schols; Erik De Clercq; Dana Gabuzda
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 8.  T cell signaling and apoptosis in HIV disease.

Authors:  Nithianandan Selliah; Jason Shackelford; Jiang-Fang Wang; Frank Traynor; Jiyi Yin; Terri H Finkel
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 9.  Apoptosis of uninfected cells induced by HIV envelope glycoproteins.

Authors:  Barbara Ahr; Véronique Robert-Hebmann; Christian Devaux; Martine Biard-Piechaczyk
Journal:  Retrovirology       Date:  2004-06-23       Impact factor: 4.602

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.